Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

14.75 +0.49 (+3.44%)

Streaming Delayed Price Updated: 9:49 AM EST, Feb 2, 2026 Add to My Watchlist

Price and Volume

Volume	146,481
Open	14.30
Bid (Size)	14.08 (300)
Ask (Size)	14.95 (300)
Prev. Close	14.26
Today's Range	13.99 - 14.75
52wk Range	3.350 - 14.94
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 28, 2026

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

December 11, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Performance

YTD	+29.5%	+29.5%
1 Month	+29.5%	+29.5%
3 Month	+38.5%	+38.5%
6 Month	+154.3%	+154.3%
1 Year	+57.4%	+57.4%

More News

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

December 11, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

November 24, 2025

From Contineum Therapeutics

Via Business Wire

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

November 20, 2025

Via Chartmill

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

November 20, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

October 30, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

September 25, 2025

Via Benzinga

This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

September 25, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 24, 2025

Via Benzinga

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

September 18, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at September Investor Conferences

August 28, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 19, 2025

Via Benzinga

Contineum (CTNM) Q2 R&D Jumps 78% ↗

August 05, 2025

Via The Motley Fool

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

August 05, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 22, 2025

Via Benzinga

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

June 25, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 15, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

May 14, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

April 28, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

March 17, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

March 12, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

March 06, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

March 04, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

March 03, 2025

From Contineum Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Contineum Therapeutics, Inc. - Common stock publicly traded?

Yes, Contineum Therapeutics, Inc. - Common stock is publicly traded.

What exchange does Contineum Therapeutics, Inc. - Common stock trade on?

Contineum Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Contineum Therapeutics, Inc. - Common stock?

The ticker symbol for Contineum Therapeutics, Inc. - Common stock is CTNM on the Nasdaq Stock Market

What is the current price of Contineum Therapeutics, Inc. - Common stock?

The current price of Contineum Therapeutics, Inc. - Common stock is 14.75

When was Contineum Therapeutics, Inc. - Common stock last traded?

The last trade of Contineum Therapeutics, Inc. - Common stock was at 02/02/26 09:49 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.